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Abstract 
Preclinical models indicate that DNA damage induces type I interferon (IFN), which is crucial for the 
induction of an anti-tumor immune response. In human cancers, however, the association between DNA 
damage and an immunogenic cell death (ICD), including the release and sensing of danger signals, the 
subsequent ER stress response and a functional IFN system, is less clear.  
Methods: Neoadjuvant-treated colorectal liver metastases (CLM) patients, undergoing liver resection in 
with a curative intent, were retrospectively enrolled in this study (n=33). DNA damage (γH2AX), RNA 
and DNA sensors (RIG-I, DDX41, cGAS, STING), ER stress response (p-PKR, p-eIF2α, CALR), type I and 
type II IFN- induced proteins (MxA, GBP1), mature dendritic cells (CD208), and cytotoxic and memory 
T cells (CD3, CD8, CD45RO) were investigated by an immunohistochemistry whole-slide tissue scanning 
approach and further correlated with recurrence-free survival (RFS), overall survival (OS), radiographic 
and pathologic therapy response.  
Results: γH2AX is a negative prognostic marker for RFS (HR 1.32, 95% CI 1.04-1.69, p=0.023) and OS 
(HR 1.61, 95% CI 1.23-2.11, p<0.001). A model comprising of DDX41, STING and p-PKR predicts 
radiographic therapy response (AUC=0.785, p=0.002). γH2AX predicts prognosis superior to the 
prognostic value of CD8. CALR positively correlates with GBP1, CD8 and cGAS. A model consisting of 
γH2AX, p-eIF2α, DDX41, cGAS, CD208 and CD45RO predicts pathological therapy response 
(AUC=0.944, p<0.001).  
Conclusion: In contrast to preclinical models, DNA damage inversely correlated with ICD and its 
associated T cell infiltrate and potentially serves as a therapeutic target in CLM. 
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Introduction 
Around 50% of all colorectal cancer (CRC) 
patients will develop liver metastases over the course 
of time [1]. Currently, only 30% of patients with 
colorectal liver metastases (CLM) are curable [2-4]. A 
profound molecular understanding of CLM could 
lead to the development of tailored therapeutic 
approaches to improve patient outcome.  
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Recent data indicate that the innate and adaptive 
immune systems appear to play a crucial role in the 
anti-tumor response against solid malignancies [5]. In 
primary CRC, the presence of tumor infiltrating T 
helper type 1 (Th1), cytotoxic T lymphocytes (CTLs) 
and memory T cells are associated with an improved 
disease-free survival (DFS) and overall survival (OS) 
[6-12]. 
This raises the question of how those T cells are 
activated within CLM. One likely candidate for T cell 
activation is type I interferon (IFN) [13-15]. Type I IFN 
is involved in the priming of T cells against 
tumor-associated antigens (TAAs) by professional 
antigen-presenting cells (APCs), as well as in the 
intratumoral accumulation of dendritic cells (DCs) 
and spontaneous cross-priming of tumor antigen- 
specific T cells in vivo [16-20]. Moreover, host type I 
IFN has been shown to be mandatory for the efficacy 
of chemotherapy [21]. 
In murine models, tumor-derived deoxyribo-
nucleic acid (DNA), incorporated by DCs, is capable 
of activating the stimulator of interferon genes 
(STING) pathway, resulting in type I IFN production 
[22, 23]. The STING pathway plays a fundamental role 
in the process of recognizing damage-associated 
molecular patterns (DAMPs), such as tumor-derived 
DNA. STING is an adapter protein, which gets 
activated by cyclic dinucleotides (CDNs), generated 
by cyclic guanosine monophosphate-adenosine 
monophosphate (GMP-AMP) synthase (cGAS), which 
in turn is directly activated by cytosolic DNA [24-26]. 
Strikingly, radiation-induced type I IFN-dependent 
anti-tumor immunity also depends on the functional 
DNA-sensing STING pathway [27]. Moreover, 
DAMPs such as double-stranded ribonucleic acid 
(dsRNA) can lead to activation of the protein kinase R 
(PKR) following an endoplasmic reticulum (ER) stress 
response, mediated by the phosphorylation of 
eukaryotic translation initiation factor 2 alpha (eIF2α), 
which results in a calreticulin (CALR) mediated 
immunogenic cell death (ICD) [28].  
In primary CRC, a type I and type II IFN-driven 
tumor microenvironment (TME) is associated with a 
Th1 immune reaction and an increased DFS [29]. 
Furthermore, mutated kirsten rat sarcoma viral 
oncogene homolog (KRAS) might abolish such a 
potential protective immune response by blunting an 
effective type I IFN response [30]. 
In this work, we evaluated this correlation in the 
clinical setting of CLM. Based on the pre-clinical data, 
we hypothesized that DNA damage would correlate 
with an increased type I IFN response and 
subsequently with a high infiltration of tumor- 
ablative immune cells, leading to an improved 
prognosis in CLM. 
In contrary to the predictions from pre-clinical 
data, DNA damage was inversely correlated with ICD 
and negatively associated with pathological response 
and clinical prognosis. 
Methods 
Patient collective 
A total of 70 patients with resectable or 
borderline resectable colorectal liver metastases 
(CLM), who underwent 3 cycles of neoadjuvant and 
adjuvant bevacizumab-based chemotherapy, 
following liver resection with a curative intent at the 
Department of Surgery of the Medical University of 
Vienna between 2005 and 2011, were retrospectively 
enrolled in this study. Of these, 33 were appropriate 
for our study (Figure S1). Patient characteristics were 
available from a prospectively maintained database 
(Table 1). Median follow-up time, 9 years (95% CI 
7.56-10.45), was calculated according to the reversed 
Kaplan-Meier method [31]. This study was conducted 
according to the reporting recommendations for 
tumor marker prognostic studies (REMARK) [32].  
Therapy application  
To achieve or improve resectability of CLM, all 
patients received a neoadjuvant treatment. Patients 
receiving chemotherapy in combination with the 
monoclonal antibody (mAb) bevacizumab, targeting 
the vascular endothelial growth factor-A (VEGF-A), 
obtained one of the following regimens: 
XELOX + bevacizumab: 21-day treatment cycle 
comprised the intravenous (IV) administration of 
bevacizumab 7.5 mg/kg over 30 min, oxaliplatin 130 
mg/m2 over 2 h and oral capecitabine 850 mg/m2 
twice daily on days 1 to 14. 
XELIRI + bevacizumab: 21-day treatment cycle 
comprised the IV administration of bevacizumab 7.5 
mg/kg over 30 min, irinotecan 250 mg/m2 and oral 
capecitabine 1000 mg/m2 twice daily on days 1 to 14. 
FOLFOX + bevacizumab: 14-day treatment cycle 
comprised the IV administration of bevacizumab 5 
mg/kg over 15 min, oxaliplatin 85 mg/m2 over 2 h, 
folinic acid 400 mg/m2 over 2 h concurrent with 
oxaliplatin, a bolus of fluorouracil 400 mg/m2 and 
fluorouracil 2400 mg/m2 over 48 h. 
FOLFIRI + bevacizumab: 14-day treatment cycle 
comprised the IV administration of bevacizumab 5 
mg/kg over 15 min, irinotecan 180 mg/m2 over 90 
min, folinic acid 400 mg/m2 over 2 h concurrent with 
irinotecan, a bolus of fluorouracil 400 mg/m2 and 
fluorouracil 2400 mg/m2 over 46 h. 
TOMOX + bevacizumab: 21-day treatment cycle 
comprised the IV administration of bevacizumab 7.5 
mg/kg over 30 min, raltitrexed 3 mg/m2 over 15 min 
and oxaliplatin 130 mg/m2 over 2 h. 
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Table 1. Patient characteristics.  
 Total no 
Demographics (n=33) 
Median age ± IQR (years) 62 ± 19 
Sex   
Male 17 (52%) 
Female 16 (48%) 
Primary tumor   
Tumor location   
Left 26 (12%) 
Right 4 (79%) 
Transverse 3 (9%) 
pT stage   
pT1 2 (8%) 
pT2 2 (8%) 
pT3 20 (76%) 
pT4 2 (8%) 
pN stage   
pN0 11 (39%) 
pN1 11 (39%) 
pN2 6 (22%) 
M stage   
M0 13 (42%) 
M1 18 (58%) 
UICC stage   
I 1 (4%) 
II 4 (15%) 
III 4 (15%) 
IV 18 (66%) 
Tumor differentiation   
Well 2 (8%) 
Moderate 19 (70%) 
Poor 6 (22%) 
Residual Tumor classification   
R0 26 (100%) 
Liver metastases   
Metastases timepoint   
Synchronous 19 (58%) 
Metachronous 14 (42%) 
Distribution   
Unilobular 15 (45%) 
Bilobular 16 (49%) 
Central 2 (6%) 
Number of lesions   
Solitary 13 (39%) 
Multiple 20 (61%) 
Neoadjuvant chemotherapy   
XELOX 19 (58%) 
FOLFIRI 4 (12%) 
FOLFOX 4 (12%) 
XELIRI 2 (6%) 
TOMOX 1 (3%) 
Fluorouracil 1 (3%) 
Irinotecan 1 (3%) 
Raltitrexed + Irinotecan 1 (3%) 
Neoadjuvant bevacizumab   
Yes 29 (88%) 
No 4 (12%) 
Neoadjuvant cetuximab   
Yes 2 (6%) 
No 31 (94%) 
Median neoadjuvant cycles ± IQR 5 ± 3 
Radiographic therapy response   
Good response (CR, PR) 15 (45%) 
Poor response (SD, PD) 18 (55%) 
Radiomorphologic therapy response   
Good response (OR, PR) 20 (60%) 
Poor response (AR) 13 (40%) 
Synchronous primary tumor resection    
Yes 2 (6%) 
No 31 (94%) 
Histology   
Adenocarcinoma - Tubular-papillary  27 (82%) 
Adenocarcinoma - Mucinous 6 (12%) 
 Total no 
Tumor differentiation   
Moderate 33 (100%) 
Residual Tumor classification   
R0 33 (100%) 
Pathologic therapy response   
Good response (0-25% viable) 9 (27%) 
Poor response (≥25% viable) 24 (73%) 
Histologic therapy response   
Good response (TRG 1-3) 4 (12%) 
Poor response (TRG 4-5) 29 (88%) 
Modified histologic therapy response   
Good response (mTRG 1-3) 17 (52%) 
Poor response (mTRG 4-5) 16 (48%) 
Mismatch repair status   
Proficient 33 (100%) 
Deficient 0 (0%) 
KRAS status   
Wild-type 13 (39%) 
Mutant 20 (61%) 
BRAF status   
Wild-type 33 (100%) 
Mutant 0 (0%) 
Median recurrence-free survival (months) 10 (95% CI 6.66-13.34) 
Median overall survival (months) 40 (95% CI 26.50-53.51) 
AR: absent response; BRAF: V‑raf murine sarcoma viral oncogene homolog B1; CI: 
confidence interval; CR: complete response; FOLFIRI: folinic acid, fluorouracil, 
irinotecan; FOLFOX: folinic acid, fluorouracil, oxaliplatin; IQR: interquartile range; 
KRAS: kirsten rat sarcoma viral oncogene homolog; Left: descending colon, 
sigmoid colon or rectum; mTRG: modified tumor regression grading; OR: optimal 
response; PD: progressive disease; PR: partial response, partial remission; Right: 
caecum or ascending colon; SD: stable disease; TOMOX: raltitrexed, oxaliplatin; 
Transverse: transverse colon; TRG: tumor regression grading; UICC: union for 
international cancer control; XELIRI: capecitabine, irinotecan; XELOX: capecitabine, 
oxaliplatin. 
 
Raltitrexed + irinotecan + bevacizumab: 21-day 
treatment cycle comprised the IV administration of 
bevacizumab 7.5 mg/kg over 30 min, raltitrexed 3 
mg/m2 over 15 min and irinotecan 350 mg/m2 over 
90 min. 
Irinotecan + bevacizumab: 21-day treatment 
cycle comprised the IV administration of 
bevacizumab 7.5 mg/kg over 30 min and irinotecan 
350 mg/m2 over 90 min. 
For patients who received chemotherapy in 
combination with the mAb cetuximab, targeting the 
epidermal growth factor receptor (EGFR), obtained 
the following regimen:  
FOLFIRI + cetuximab: 28-day treatment cycle 
comprised the IV administration of cetuximab, 
starting with a loading dose of 400 mg/m2 over 2 h, 
followed by 250 mg/m2 over 1 h every week, 
irinotecan 180 mg/m2 over 90 min, folinic acid 400 
mg/m2 over 2 h concurrent with irinotecan, a bolus of 
fluorouracil 400 mg/m2 and fluorouracil 2400 mg/m2 
over 48 h, given on days 1 and 15. 
For patients receiving chemotherapy alone, they 
obtained either XELOX as described above or oral 
capecitabine 1250 mg/m2 twice daily for 2 weeks in a 
21-day treatment cycle. 
The type of regimen and dose alteration was 
based on the decision of the local multidisciplinary 
tumor board team. The different chemotherapy 
regimens were preferentially given in combination 
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with bevacizumab as long as there were no 
contraindications, such as history of gastrointestinal 
perforation, fistulas, wound healing complications, 
challenging hypertension, proteinuria, arterial or 
venous thromboembolic events, bleedings, congestive 
cardiac failure, current infection or neutropenia. 
Evaluation of radiographic therapy response 
Radiographic therapy response was determined 
by an expert radiologist (D.T.) of the Department of 
Radiology and Nuclear Medicine of the Medical 
University of Vienna, who was blinded to clinical 
data. 
Change of metastases diameter between pre- and 
post-neoadjuvant treatment was evaluated by 
contrast-enhanced computed tomography (CT) or 
magnetic resonance imaging (MRI). Metastases were 
classified as complete response (CR), partial response 
(PR), stable disease (SD) or progressive disease (PD), 
according to the response evaluation criteria in solid 
tumors (RECIST) 1.1 [33]. Briefly, CR (vanishing of all 
lesions), PR (decrease in ≥30% size), SD (decrease in 
<30% size) and PD (increase in ≥20% size). Patients 
were considered as good (CR, PR) or poor (SD, PD) 
responders. 
Evaluation of radiomorphologic therapy response 
Radiomorphologic therapy response was 
determined by an expert radiologist (D.T.) of the 
Department of Radiology and Nuclear Medicine of 
the Medical University of Vienna, who was blinded to 
clinical data. 
Change of metastases morphology between pre- 
and post-neoadjuvant treatment was evaluated by 
contrast-enhanced CT scans according to the novel 
morphological response criteria [34-36]. Briefly, target 
lesions were evaluated and grouped according to 
their overall attenuation (heterogeneous, mixed or 
homogeneous/hypoattenuating), tumor-liver inter-
face (defined, variable or sharp) and peripheral rim 
enhancement (may be present, if primarily present, 
incompletely resolved or if primarily present, 
completely resolved). Group 1 was classified by a 
homogeneous overall attenuation, a sharply defined 
tumor-liver interface and a completely resolved 
peripheral rim enhancement. Group 3 was 
characterized by a heterogeneous overall attenuation, 
a poorly defined tumor-liver interface and absence of 
a peripheral rim enhancement or if primarily present, 
no resolution. Group 2 was classified by an 
intermediate morphology, which could not be scored 
as group 1 or 3. Optimal response (OR) was defined 
by a change from group 3 or 2 to group 1, partial 
response (PR) was considered for a change from 
group 3 to group 2 and absent response (AR) if there 
was no group change or progression from group 2 to 
group 3. Patients were considered as good (OR, PR) or 
poor (AR) responders. 
Evaluation of pathologic therapy response 
An expert hepatobiliary pathologist (J.S.) of the 
Department of Pathology of the Medical University of 
Vienna, who was blinded to clinical data, assessed the 
histologic characteristics of hematoxylin and eosin 
(H&E) stained specimens.  
Pathologic therapy response was semi- 
quantitatively assessed by the amount of vital tumor 
cells, as a percentage relative to all tumor cells. Areas 
of usual necrosis (UN), indicating an insufficient 
treatment effect, were considered as part of vital 
tumor cells. However, infarct-like necrosis (ILN), 
characterizing a therapeutic response to chemo-
therapy, was considered as non-vital tumor cells [37]. 
On this basis, we allocated each specimen into one 
quartile (≥75%, 50-75%, 25-49% or <25% viable tumor 
cells).  
Evaluation of histologic therapy response 
An expert hepatobiliary pathologist (J.S.) of the 
Department of Pathology of the Medical University of 
Vienna, who was blinded to clinical data, assessed the 
histologic characteristics of H&E stained specimens.  
Histologic therapy response was assessed 
semi-quantitatively according to the tumor regression 
grading (TRG) [38]. Briefly, TRG1 was classified by 
the absence of tumor cells replaced by extensive 
fibrosis. TRG2 represented seldom remaining tumor 
cells dispersed through extensive fibrosis. TRG3 
characterized more remaining tumor cells dispersed 
through predominant fibrosis. TRG4 described large 
amount of vital tumor cells predominating over 
fibrosis. TRG5 contained mostly vital tumor cells 
without any fibrosis.  
Moreover, we incorporated the consideration of 
ILN into a modified TRG (mTRG) [37]. 
For the declaration of hepatic steatosis, a cut-off 
of 5% steatotic cells of patient matched normal liver 
tissue was used [39].  
Analysis of mutation status 
Kirsten rat sarcoma viral oncogene homolog 
(KRAS) and V-raf murine sarcoma viral oncogene 
homolog B1 (BRAF) mutation status of CLM was 
determined as previously described [40]. Briefly, 
genomic DNA was extracted from tissue blocks and 
exon 2 and 3 of the KRAS gene and exon 15 of the 
BRAF gene were polymerase chain reaction (PCR) 
amplified with AmpliTaq Gold® DNA polymerase 
(Applied Biosystems, Fisher Scientific, Vienna, 
Austria) and corresponding oligonucleotide primers 
(Table S1). Excess of primers and deoxynucleotides 
(dNTPs) was removed by incubation of 5 µL PCR 
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product with 2.5 U exonuclease I (GE Healthcare Life 
Sciences, Vienna, Austria) and 2.5 U shrimp alkaline 
phosphatase (SAP; GE Healthcare Life Sciences) at 
37°C for 1 h. Enzymes were further heat inactivated at 
70°C for 15 min, following sequence analysis with 1-2 
µL of the purified PCR product and 4 pmol primers 
using the BigDye™ Terminator Cycle Sequencing Kit 
(Applied Biosystems) according to the manufacturer’s 
instructions. Excess of BigDye™ Terminator 
nucleotides was removed by centrifugation with 
Centri-Sep™ Spin Columns (Invitrogen, Fisher 
Scientific, Vienna, Austria). Separation and analysis of 
the sequencing reaction products were performed 
with an Applied Biosystems 3130 Genetic Analyzer 
(Applied Biosystems) according to manufacturer’s 
protocol. 
Analysis of mismatch repair status 
Mismatch repair (MMR) status, proficient or 
deficient, was determined by immunohistochemistry 
(IHC) [41, 42]. For this purpose, MutL homolog 1 
(MLH1; Ventana Medical Systems Inc.) and MutS 
protein homolog 2 (MSH2; Cell Marque, Rocklin, CA, 
USA) were stained by an automated IHC slide 
staining BenchMark ULTRA system (Ventana 
Medical Systems Inc.) according to manufacturer’s 
protocol (Table S2). Briefly, samples were 
deparaffinized following heat-induced epitope 
retrieval (HIER) at 95°C for 52 min at pH 8 
(ready-to-use solution). Antibody binding was 
visualized using the ultraView Universal DAB 
Detection Kit (Ventana Medical Systems Inc.). Slides 
were counterstained with hematoxylin (Ventana 
Medical Systems Inc.) and sealed with coverslips. All 
samples were evaluated by an expert hepatobiliary 
pathologist (J.S.) of the Department of Pathology of 
the Medical University of Vienna, who was blinded to 
clinical data. Tumor showing loss of MLH1 and 
MSH2 expression were classified as mismatch repair 
deficient. Matched nuclear staining of lymphocytes 
served as an internal positive control. 
Immunohistochemistry 
Formalin-fixed paraffin-embedded (FFPE) tissue 
of CLM was obtained from the Department of 
Pathology of the Medical University of Vienna. 
Consecutive 1 µm thick slices were cut from FFPE 
tumor tissue. Paraffin wax was melted at 60°C for 2 h 
and, subsequently, slides were deparaffinized in 
xylene (Fisher Scientific, Pittsburgh, PA, USA) and 
rehydrated in declining dilutions of ethanol. For 
HIER, slides were incubated in 10 mM sodium citrate 
(Sigma-Aldrich, St. Louis, MO, USA) containing 
0.05% Tween 20 (Sigma-Aldrich) at pH 6.0 or in 10 
mM tris(hydroxymethyl)aminomethane (Merck 
Millipore, Darmstadt, HE, DE) and 1 mM 
ethylenediaminetetraacetic acid (EDTA; Sigma- 
Aldrich) containing 0.05% Tween 20 at pH 9.0 and 
heated up in pressure cooker until 121°C. 
Consequently, slides were cooled down to room 
temperature (RT) and permeabilized with 0.2% Triton 
X-100 (Sigma-Aldrich) in phosphate-buffered saline 
(PBS) for 5 min at RT. Endogenous peroxidase activity 
was blocked with 0.3% hydrogen peroxide (Merck 
Millipore) in PBS for 10 min at RT in the dark. 
Afterwards, slides were incubated with 5% normal 
horse serum in PBS (VECTASTAIN Elite ABC HRP 
Kit; Vector Laboratories, Burlingame, CA, USA) for 20 
min at RT. Primary antibodies (Table S2) were 
incubated for 1 hr at RT in a humidified chamber. 
Afterwards biotinylated horse anti-mouse IgG/anti- 
rabbit IgG secondary antibody (VECTASTAIN Elite 
ABC HRP Kit; Vector Laboratories) was applied for 30 
min at RT, following incubation with the AB reagent 
(VECTASTAIN Elite ABC HRP Kit; Vector 
Laboratories) for 30 min at RT in the dark. Color 
development was conducted with the DAB 
Peroxidase (HRP) Substrate Kit (Vector Laboratories). 
Slides were counterstained with Mayer's hemalum 
solution (Merck Millipore), dehydrated in ascending 
dilutions of ethanol, incubated in n-Butyl acetate 
(Fisher Scientific) for 2 min at RT, mounted with 
Entellan (Merck Millipore) and sealed with coverslips.  
CD3, CD8, CD45RO, GBP1, Ki-67 and MxA were 
stained by an automated immunohistochemistry 
staining Benchmark XT system (Ventana Medical 
Systems Inc., Tucson, AZ, USA) using the reagents 
and steps according to the manufacturer’s protocol. 
Briefly, following deparaffinization, HIER was 
performed at 42°C for 30 min at pH 9 (ready-to-use 
solution). Antibody binding was visualized using the 
ultraView Universal DAB Detection Kit (Ventana 
Medical Systems Inc.). Slides were counterstained 
with Mayer’s hematoxylin (Zymed Laboratories Inc., 
San Fransisco, CA, USA) and sealed with coverslips. 
Whole-slide tissue cell quantification 
Microscopic images of whole-slide tissue 
sections were automatically acquired with 
TissueFAXS scanning systems (TissueGnostics 
GmbH, VIE, AUT), using a Zeiss Observer Z1 
microscope (Carl Zeiss AG, Oberkochen, BW, GER) 
equipped with a SCAN IM 12-slide scanning stage 
(Marzhauser Wetzlar GmbH & Co. KG, Wetzlar, HE, 
GER) and a Baumer HXG40c camera (Baumer Group, 
Frauenfeld, TG, CHE), operated by TissueFAXS 4.2 
Slides software (TissueGnostics). Acquisition was 
performed with an EC Plan-Neofluar 20x/0.5 M27 
objective (Zeiss). Acquired imaging data was 
analyzed with the image analysis software 
StrataQuest 5.0.1.264 (TissueGnostics). 
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Two different regions were analyzed within the 
CLM: (i) tumor (TU) and (ii) invasive margin (IM; 
tumor/adjacent liver border). For this purpose, the 
clear distinguishable tumor area was marked 
manually and a standardized invasive margin area, 
with an exact width of 500 µm on each side of the 
tumor/adjacent liver border, was created 
automatically by the analysis software (Figure S2). 
For absolute cell quantification a (i) nuclei mask 
was programmed, which detects all single cells on the 
basis of the cell nuclei staining and morphology. This 
nuclei mask was further used for the generation of an 
(ii) antibody detection mask, identifying the antibody 
specific staining pattern (membrane, cytoplasmic or 
nucleus) of the differently used antibodies 
(Figure S3). 
Values are given as percentages of nuclei and 
antibody specific-stained single cells out of all 
nuclei-stained single cells at each region of interest. 
All computerized evaluations were visually 
crosschecked for reliability. 
Statistics 
Recurrence-free survival (RFS) was the primary 
endpoint of this study and defined as the time 
between surgery of CLM and observation of the first 
recurrence (local or distant) or cancer-related death. 
Overall survival (OS), defined as the time between 
resection of CLM and cancer-related death, 
radiographic therapy response and pathologic 
therapy response were secondary endpoints. If a 
patient had neither a recurrence nor a cancer-related 
death, RFS or OS was censored at the date of the last 
follow-up or known to be alive.  
All statistical analyses were computed with R 
version 3.4.1 [43]. Percentage of marker panel events 
were log2 transformed to achieve approximate normal 
distributions. Missing IHC (up to 24% for CD3 values) 
and clinical data (radiographic therapy response, 
radiomorphologic therapy response, histology, 
pathologic therapy response, histologic therapy 
response, and modified histologic therapy response) 
were imputed with values estimated by the predictive 
mean matching method using R-package “mice” 
(version 2.30; table without imputed values is shown 
in Table S3). 
Principal component analysis (PCA), correlation 
matrix plots and Pearson’s correlation coefficients for 
IM and TU were calculated with intrinsic R 
commands and R-package “corrplot” (version 0.77). 
P-values of the “corrplot” were corrected according to 
the false discovery rate (FDR) [44]. 
Univariate Cox regression analyses were 
calculated with R commands. Hazard ratios (HR) and 
corresponding 95% confidence intervals (CI) were 
plotted with R-package “forestplot” (version 1.8). 
Prognostics models were computed with an adaptive 
elastic net approach for censored data using the 
R-package “hdnom” (version 4.8.9000) and are 
illustrated by nomograms. For this purpose, the 
“hdcox.aenet” command with a 4-fold internal 
cross-validation and lambda selection based on the 
one standard error cut-off method (“lambda.1se”), 
which gives the most regularized model in which the 
error is within one standard error of the minimum 
mean cross-validated error, was used. The final 
prognostic models were further bootstrap-based 
validated at several time points and results are 
depicted by corresponding plots. The model-predictor 
was further dichotomized into a high-risk and 
low-risk group to illustrate the impact of each final 
model on clinical outcome, which is illustrated by 
Kaplan-Meier survival estimates. As the survival 
estimates are originated from the multivariable 
models, no censored patients are included.  
To predict radiographic and pathologic therapy 
response with the marker panel, least absolute 
shrinkage and selection operator (LASSO) logistic 
regression models were generated with the R-package 
“glmnet” (version 2.0-10), internally cross-validated 
and regularized as described above. For each outcome 
(radiographic or pathologic) the model with the best 
prediction performance, based on the area under the 
receiver operating characteristic (ROC) curve (AUC), 
was selected. Boxplots of the corresponding 
model-values are illustrated next to the AUC plots. 
The Venn diagram was plotted using R-package 
“VennDiagram” (version 1.6.17). All p-values were 
2-sided and considered as statistically significant if 
<0.05. 
Results 
Marker panel events at the invasive margin and 
tumor area are correlated 
We determined proteins involved in DNA 
damage (γH2AX), RNA and DNA sensors (RIG-I, 
DDX41, cGAS, STING), ER stress response (p-PKR, 
p-eIF2α, CALR), type I and type II IFN-induced 
proteins (MxA and GBP1 respectively) and 
tumor-infiltrating immune cells, such as activated 
DCs (CD208) and T cells (CD3, CD8, CD45RO) in 
patients with CLM by the use of a quantitative 
immunohistochemistry approach (Figure 1A).  
To evaluate the data explaining variance of our 
marker panel, we initially performed a principal 
component analysis (PCA). Strikingly, nearly all 
vectors, indicating the impact of each marker on the 
PCs, pointed in the same direction within the PC1 
(Figure 1B). This implies that the biological raised 
question in this work accounts for the highest 
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variance in the data (i.e., PC1). Moreover, IM and TU 
vectors of each individual marker were 
approximately overlapping, indicating an association 
between each other. The latter observation was 
further confirmed by a correlation analysis of the 
marker panel values at the IM and TU (Figure 1C). 
Taking all these facts into account, we conducted all 
further analysis only with the marker panel values at 
the IM. 
DNA damage and ER stress response are inversely 
associated with recurrence-free survival 
We assessed the association of our marker panel 
with recurrence-free survival (RFS). We first 
conducted a univariate Cox regression analysis 
(Figure 2A). Interestingly, the amount of DNA 
damage, represented by γH2AX, was associated with 
a shorter RFS (HR 1.32, 95% CI 1.04-1.69, p=0.023). In 
contrast, ER stress response, characterized by the 
exposure of calreticulin (CALR), was linked with a 
longer RFS (HR 0.83, 95% CI 0.69-0.98, p=0.03). In this 
line, cytotoxic T cells (CTLs; CD8) were also related 
with a longer RFS (HR 0.67, 95% CI 0.50-0.89, 
p=0.007). 
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Figure 1. Marker panel events at the invasive margin and tumor area are correlated with each other. (A) Studydesign. (B) Principal component analysis (PCA) of 
marker panel values at the invasive margin (IM) and tumor area (TU). Each dot represents a CLM sample. PC1 is depicted on the x-axis and PC2 on the y-axis. Percentage of data 
variance explained by each PC is indicated. Arrows specify vectors for each individual marker at the IM and TU, indicating the impact of the PCs. (C) Correlation matrix plots 
for each individual marker at the IM and TU. Pearson’s correlation coefficients are indicated in the upper right boxes. Histogram of corresponding value distributions at the IM 
and TU are shown in the upper left and lower right boxes, respectively. Dashed lines in the lower left boxes represent linear regressions. ***p<0.001; CALR: calreticulin. CD: 
cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: 
guanylate binding protein 1; IM: invasive margin; MxA: interferon-induced guanosine triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation initiation 
factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible gene I; STING: stimulator of interferon genes; TU: tumor area; γH2AX: 
phosphorylated-histone H2AX. 
 
Furthermore, we conducted a univariate Cox 
regression analysis for the clinical characteristics 
(Figure 2B). The clinical characteristics that 
contributed with statistical significance to RFS were 
distribution of metastases (HR 0.31, 95% CI 0.15-0.62, 
p=0.001), number of metastases (HR 1.20, 95% CI 
1.07-1.36, p=0.003), tumor vitality (HR 1.02, 95% CI 
1.01-1.04, p=0.004), modified histologic response (HR 
2.68, 95% CI 1.24-5.80, p=0.013) and KRAS status (HR 
2.32, 95% CI 1.04-5.15, p=0.039). 
Additionally, we assessed a multivariable 
analysis for RFS by combining the marker panel and 
clinical variables. For this intent, we built an internally 
cross-validated adaptive elastic-net model (Figure 
2C), which was further bootstrap-validated at certain 
time-points (Figure 2D). The model contributing 
statistical significance to the 5-year RFS probability 
consisted of the markers γH2AX, CALR, CD8, GBP1, 
p-PKR and CD208, as well as the clinical variables 
metastases distribution, KRAS status, modified 
histologic therapy response, timing of metastases, 
histologic therapy response and histology. Apart from 
the CLM distribution, γH2AX had the strongest 
association (negative) with RFS. 
The prognostic power of the model for RFS 
revealed a stable median AUC of ~0.8 over time. On 
the basis of the statistically significant model for RFS, 
patients were further dichotomized into high-risk and 
low-risk groups. Comparison between the two 
different groups revealed a statistically significant 
different RFS probability (p<0.001; Figure 2E). 
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Figure 2. DNA damage and ER stress response are inversely associated with recurrence-free survival. (A) Forest plot indicating hazard ratios (HR; black squares) 
and corresponding 95% confidence intervals (CI; grey horizontal lines) of marker panel (log2 % values) and (B) clinical characteristics for RFS. The square size correlates with the 
range of the 95% CI. The grey vertical line represents the no effect point. Green and red color indicates a statistically significant positive or negative effect, respectively. HR, 
corresponding 95% CI (within the brackets) and p-values are shown. (C) Internal cross-validated adaptive elastic-net model for RFS is illustrated by a nomogram. A straight 
upward line to the “Points” axis is drawn for each individual patient clinical characteristic and marker expression (log2 % values), following a straight downward line to the “Total 
Points” axis, the “Linear Predictor” and the corresponding “5-Year Recurrence-free Survival Probability”. (D) Bootstrap validation of nomogram model over time. The area 
under the receiver operating characteristic (ROC) curve (specified on the ordinate) is depicted over time (months; specified on the abscissa). The mean (solid blue line), median 
(dashed blue line), 25% and 75% quantiles (dark grey area), minimum and maximum (light grey area) of the area under the ROC curve are illustrated. (E) RFS probability for 
“high-risk” and “low-risk” groups, which are dichotomized from the nomogram model, is specified on the ordinate. Time (months) is specified on the abscissa. AR: absent 
response; CALR; calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; CR: complete response; DDX41: 
aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; IM: invasive margin; KRAS: kirsten rat sarcoma viral oncogene homolog; mTRG: 
modified tumor regression grading; mut: mutant; MxA: interferon-induced guanosine triphosphate-binding protein MxA; OR: optimal response; p-eIF2α: 
phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; PD: progressive disease; PR: partial response, partial remission; RIG-I: 
retinoic acid inducible gene I; SD: stable disease; STING: stimulator of interferon genes; TRG: tumor regression grading; TU: tumor area; wt: wild-type; γH2AX: 
phosphorylated-histone H2AX. 
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Figure 3. DNA damage and DNA sensor DDX41 are negatively associated with overall survival. (A) Forest plot indicating hazard ratios (HR; black squares) and 
corresponding 95% confidence intervals (CI; grey horizontal lines) of marker panel (log2 % values) and (B) clinical characteristics for OS. The square size correlates with the range 
of the 95% CI. The grey vertical line represents the no effect point. Green and red colors indicate a statistically significant positive or negative effect, respectively. HR, 
corresponding 95% CI (within the brackets) and p-values are shown. (C) Internal cross validated adaptive elastic-net model for OS is illustrated by a nomogram. A straight 
upward line to the “Points” axis is drawn for each individual patient clinical characteristic and marker expression (log2 % values), following a straight downward line to the “Total 
Points” axis, the “Linear Predictor” and the corresponding “5-Year Overall Survival Probability”. (D) Bootstrap validation of nomogram model over time. The area under the 
receiver operating characteristic (ROC) curve (specified on the ordinate) is depicted over time (months; specified on the abscissa). The mean (solid blue line), median (dashed 
blue line), 25% and 75% quantiles (dark grey area), minimum and maximum (light grey area) of the area under the ROC curve are illustrated. (E) OS probability for “high-risk” 
and “low-risk” groups, which are dichotomized from the nomogram model, is specified on the ordinate. Time (months) is specified on the abscissa. AR: absent response; CALR; 
calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine monophosphate synthase; CR: complete response; DDX41: 
aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; IM: invasive margin; KRAS: kirsten rat sarcoma viral oncogene homolog; mTRG: 
modified tumor regression grading; mut: mutant; MxA: interferon-induced guanosine triphosphate-binding protein MxA; OR: optimal response; p-eIF2α: 
phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; PD: progressive disease; PR: partial response, partial remission; RIG-I: 
retinoic acid inducible gene I; SD: stable disease; STING: stimulator of interferon genes; TRG: tumor regression grading; TU: tumor area; wt: wild-type; γH2AX: 
phosphorylated-histone H2AX 
 
DNA damage and DNA sensor DDX41 are 
negatively associated with overall survival 
To investigate the association impact of our 
marker panel with OS we conducted a univariate Cox 
regression analysis (Figure 3A). The amount of 
γH2AX, the DNA sensor DDX41, as well as p-PKR 
were negatively associated with OS (HR 1.61, 95% CI 
1.23-2.11, p<0.001; HR 1.22, 95% CI 1.04-1.44, p=0.017 
and HR 1.33 95% CI 1.07-1.64, p=0.009; respectively). 
With respect to the clinical characteristics and 
their impact on OS, a univariate Cox regression 
analysis revealed that metastases distribution (HR 
0.37, 95% CI 0.18-0.76, p=0.007), number of metastases 
(HR 1.15, 95% CI 1.01-1.30, p=0.035), radiographic 
therapy response (HR 3.27, 95% CI 1.38-7.71, p=0.007) 
and KRAS status (HR 2.65, 95% CI 1.10-6.40, p=0.03) 
had a statistically significant association with OS (Fig. 
3B). 
Next, we performed an adaptive elastic-net 
model for the marker panel and the clinical 
characteristics together, as described above. The 
analysis revealed a model, which included the 
markers γH2AX, CD8 and DDX41, as well as the 
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clinical variables such as metastases distribution, 
radiographic therapy response and KRAS status, 
which all together contributed statistical significance 
to the 5-year OS probability (Figure 3C). Again, 
γH2AX was the strongest molecular parameter, which 
had a negative impact on OS. The model was further 
bootstrap-validated over time, which revealed a stable 
median AUC of ~0.9 (Figure 3D). On the basis of the 
statistically significant model, patients were further 
dichotomized into high-risk and low-risk groups, 
which revealed a significant different OS probability 
between the two groups (p<0.001; Figure 3E). 
ER stress response correlates with a functional type 
II IFN system and cytotoxic T cell infiltration 
In order to investigate the biological relationship 
between the different markers of our marker panel, 
we generated a correlogram (Figure 4). Strikingly, ER 
stress response (CALR) was positively correlated with 
a functional type II IFN system, represented by the 
expression of GBP1 (r=0.67, FDR<0.001), CTLs (CD8; 
r=0.54, FDR=0.015) and the DNA sensors cGAS 
(r=0.48, FDR=0.005). A functional type II IFN system 
(GBP1) was further positively correlated with 
memory T cells (CD45RO; r=0.46, FDR=0.04) and the 
DNA sensor cGAS (r=0.47, FDR=0.012). Pan T cells 
(CD3) were positively correlated with cytotoxic T cells 
(CD8; r=0.56, FDR=0.001). The RNA sensor RIG-I 
showed a positive correlation with a higher cell 
proliferation index, represented by Ki-67 (r=0.39, 
FDR=0.047). 
DNA sensors DDX41, STING and p-PKR predict 
radiographic therapy response 
Next, we investigated the association of our 
marker panel with radiographic as well as 
radiomorphologic therapy response (Figure S4A-C). 
Patients were dichotomized into good responder (CR, 
PR and OR, PR, respectively) and poor responder (SD, 
PD and AR, respectively). 
We conducted a univariate analysis between 
good and poor responders, which revealed the DNA 
sensor DDX41 as the only statistically significant 
marker associated with radiographic therapy 
response (p=0.013; Figure 5A). With respect to 
radiomorphologic response, there was a statistically 
significant association seen between γH2AX and good 
or poor response (p=0.043; Figure S5A). 
We further generated a multivariable logistic 
regression model, using a LASSO approach. The 
statistically significant model, 
which predicted radiographic 
therapy response, was 
comprised of the markers 
DDX41, STING and p-PKR, 
(AUC=0.785, p=0.002; Figure 
5B). The coefficients of DDX41 
and p-PKR comparted a 
negative impact to STING, 
which was positively asso-
ciated with radiographic 
therapy response (Figure 5C). 
Of note, within a multivariable 
logistic regression model for 
radiomorphologic response, 
γH2AX remained the only 
statistically significant asso-
ciated marker, which had a 
negative impact on treatment 
response (AUC=0.712, p=0.022; 
Figure 5B-C). 
 
 
 
 
Figure 4. ER stress response correlates with a functional type II IFN system. A correlogram of marker panel 
values is shown. Pearson’s correlation coefficients (r) for all markers are given in the lower triangle. Colored circles 
indicate statistically significant correlations, corrected according to the false discovery rate (FDR<0.05). Size and color 
intensity of the circles are related to the correlation coefficients. Blue color represents positive and red color negative 
correlations. CALR: calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine 
monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 
1; MxA: interferon-induced guanosine triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation 
initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible gene I; STING: stimulator of 
interferon genes; γH2AX: phosphorylated-histone H2AX 
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Figure 5. DNA sensors DDX41, STING and p-PKR predict radiographic therapy response. Comparison of the marker panel between good and poor (A) 
radiographic and (D) pathologic responders is indicated by box-and-whisker plots, containing the individual values (Mann-Whitney U test). The bold horizontal line represents 
the median, the top and bottom of the box illustrate the first and third quartiles, and the whisker represent 1.5 times the interquartile range (IQR). Multivariable logistic 
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regression model (LASSO) for the prediction of (B) radiographic and (E) pathologic response is illustrated by a receiver operating characteristic (ROC) curve. False positive rate 
(FPR) is specified at the abscissa and true positive rate (TPR) at the left ordinate. The ROC curve is color-coded according to the threshold values defined on the right ordinate. 
The black 45° line represents the line of identity. Area under the curve (AUC) and corresponding p-values are indicated. Comparison of the multivariate logistic regression model 
between good and poor (C) radiographic and (F) pathologic responders. CALR: calreticulin; CD: cluster of differentiation; cGAS: cyclic guanosine monophosphate‑adenosine 
monophosphate synthase; DDX41: aspartate-glutamate-alanine-aspartate-box helicase 41; GBP1: guanylate binding protein 1; MxA: interferon-induced guanosine 
triphosphate-binding protein MxA; p-eIF2α: phosphorylated-eukaryotic translation initiation factor 2 alpha; p-PKR: phosphorylated-protein kinase R; RIG-I: retinoic acid inducible 
gene I; STING: stimulator of interferon genes; γH2AX: phosphorylated-histone H2AX 
 
DNA damage, DNA sensors DDX41 and cGAS, ER 
stress, DCs and memory T cells predict pathologic 
therapy response 
We examined the association of our marker 
panel with pathologic, histologic as well as with 
modified histologic therapy response (Figure S4D-E). 
Patients were dichotomized into good responders 
(0-25% viable, TGR 1-3 and mTRG 1-3, respectively) 
and poor responders (≥25% viable, TRG 4-5 and 
mTRG 4-5, respectively). 
A univariate analysis between good and poor 
responder revealed a statistically significant 
correlation between cGAS and pathologic therapy 
response, as well as between p-eIF2α and CD208 and 
modified histologic therapy response (p=0.014, 
p=0.016 and p=0.035 respectively; Figure 5D and 
Figure S6D). Regarding the evaluation of histologic 
therapy response, there was no association between 
any marker and good or poor response (Figure S6A). 
Next, we performed a multivariable logistic 
regression analysis, using a LASSO approach. The 
model contributing statistical significance to the 
prediction of pathologic therapy response comprised 
the markers γH2AX, DDX41, cGAS, p-eIF2α, CD208 
and CD45RO (AUC=0.944, p<0.001; Figure 5E). 
Within this model the individual coefficients of 
γH2AX, DDX41, p-eIF2α, CD208 and CD45RO had a 
negative impact compared to cGAS, which was 
positively associated with pathologic therapy 
response (Figure 5F). 
In contrast, a multivariable evaluation of 
histologic therapy response revealed no association 
between any marker and response to therapy 
(Figure S6B-C). However, multivariable analysis for 
modified histologic therapy response revealed a 
statistically significant model, which comprised the 
markers cGAS, p-eIF2α, MxA, GBP1 and CD208 
(AUC=0.926, p<0.001; Figure S6E). The individual 
coefficients of cGAS and GBP1 were positively 
associated with modified histologic response 
compared to p-eIF2α, MxA and CD208, which were 
negatively associated (Figure S6F). 
DNA damage, ER stress response and DNA sensor 
DDX41 are associated with therapy response and 
clinical outcome 
We summarized the contribution of each 
individual marker to one of the two prognostics (RFS 
and OS) and predictive (radiographic and pathologic 
therapy response) models in a Venn diagram (Figure 
6). This summary highlights the role of DNA damage 
(γH2AX), ER stress response (CALR) and the DNA 
sensor DDX41, which contributed the most to the 
preoperative evaluation of radiographic therapy 
response, RFS and postoperative evaluation of 
pathologic therapy response. 
 
 
Figure 6. DNA damage, ER stress response and DNA sensor DDX41 are 
associated with therapy response and clinical outcome. Venn diagram 
illustrating the overlap between the marker panel and the four different multivariable 
models (RFS, OS, radiographic and pathologic response). Arrows indicate positive or 
negative coefficients for each marker. The coefficients of all markers pointed in the 
same direction (positive or negative) within the four different multivariable models. 
 
Discussion 
Recent murine data gave evidence that the 
initiation of a so called bona fide ICD depends on the 
release of danger signals, such as DNA damage 
[45-48], which gets sensed in part by the cGAS-STING 
pathway [26, 49, 50], following the induction of a type 
I IFN response [15, 18], which links the innate and 
adaptive immune system and thereby supports an 
anti-tumor immune response.  
In contrast to murine data, we found in our 
clinical dataset that DNA damage (γH2AX) is 
negatively associated with RFS, OS and pathologic 
therapy response. DNA damage has an inverse 
impact on the clinical outcome compared to CTL 
(CD8) infiltration, as well as ER stress response 
(CALR). Correspondingly, the DNA sensor DDX41 is 
associated with a shorter OS, as well as poor 
radiographic and pathologic therapy response. The 
negative prognostic and predictive role of DNA 
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damage can be explained by its dual role, which on 
one hand promotes an ICD, while on the other hand 
facilitates the assembly of DNA repair proteins, which 
favors tumor cell survival [51, 52]. In line with the 
latter role, a recent study demonstrated that the 
expression of DNA damage at the time of diagnosis 
predicts poor treatment response to chemotherapy in 
breast cancer patients [53]. Moreover, DNA damage 
has been reported as an inducer of tumorigenicity and 
stemness in patient-derived glioma cells [54]. The 
negative impact of γH2AX on RFS and OS suggests 
that patients with CLM, which develop high amounts 
of DNA damage, render a “high-risk” group of 
patients throughout the course of the disease.  
The DNA sensor DDX41, which is upstream of 
the STING pathway, also has a dual role in 
tumorigenesis [55]. On one hand, DDX41 serves as a 
tumor suppressor in hematological malignances, 
while in solid tumors DDX41 has been reported as a 
tumor promotor. Here, we strengthen DDX41 as a 
negative prognosticator for OS and negative predictor 
for radiographic and pathologic therapy response.  
Our findings indicate that STING and cGAS 
induction positively correlate with response to 
therapy, but this induction is not associated with 
activation of the type I IFN pathway (MxA) or DNA 
damage, as the later negatively correlates with 
therapy response. However, DNA damage appears to 
mediate a stress response, as observed by the negative 
impact of up-regulated p-PKR and p-eIF2α. This 
suggests that part of the ER stress response is 
involved in the negative impact of DNA damage on 
therapeutic unresponsiveness. 
The differences seen in our clinical observations 
compared to murine studies, which describe an 
immunostimulatory effect of DNA damage, might be 
explained by the fact that DNA damage was rather 
shortly induced before the analysis [27]. In contrast, in 
our clinical setting, neoadjuvant therapy was usually 
finished four weeks before liver resection. Thus, we 
propose that the protein expression pattern observed 
in our CLM is derived from spontaneously occurring 
endogenous stimuli, rather than from exogenously 
induced DNA damage by chemotherapy.  
The multivariable analysis depicted in the 
nomogram reveals that the negative association of 
γH2AX has a bigger impact on OS compared to the 
positive association of CTLs (CD8). Similarly, γH2AX 
has a higher influence on RFS than CTLs (CD8). 
Previously, tumor-infiltrating immune cells were 
considered as the strongest prognostic parameter in 
primary CRC as well as CLM [9, 56]. Our 
multivariable analysis now indicates that DNA 
damage is even more relevant for prognosis than 
tumor-infiltrating immune cells in our dataset. This 
finding highlights the impact of DNA damage for 
disease progression and calls for its further 
understanding as a prognostic marker and as a 
potential therapeutic target in a clinical setting.  
Furthermore, we demonstrate the prognostic 
relevance of so called “eat-me” signals such as CALR 
[47] in CLM, which has been shown previously in 
treatment-naïve primary CRC [57, 58]. The exposure 
of CALR correlated with a functional type II IFN 
system (GBP1), CTLs (CD8) and the expression of the 
DNA sensor cGAS. Additionally, in regards of RFS, 
CTLs (CD8) are associated with the activation of ER 
stress response (CALR) and a functional type II IFN 
system (GBP1) but not with the type I IFN pathway 
(MxA). 
Taken together, translating data from murine 
models to a clinically applied human setting suggests 
a key role of DNA damage and sensing, as well as a 
bona fide ICD on the clinical outcome during the 
course of CLM. Surprisingly, those interactions were 
already significant on a very limited number of 
patients, suggesting a high biological impact. 
Certainly, those findings should be further verified in 
a larger cohort, as well as in different disease stages 
and cancer types. In this line, a recently developed 
positron-emission tomography (PET) imaging agent 
directed against γH2AX could serve as an attractive 
approach to monitor current treatment response and 
clinical outcome [59]. 
Abbreviations 
APCs: antigen-presenting cells; AR: absent 
response; AUC: area under the receiver operating 
characteristic curve; BRAF: V‑raf murine sarcoma 
viral oncogene homolog B1; CALR: calreticulin; CD: 
cluster of differentiation; CDNs: cyclic dinucleotides; 
cGAS: cyclic guanosine monophosphate‑adenosine 
monophosphate synthase; CI: confidence interval; 
CLM: colorectal liver metastases; CR: complete 
response; CRC: colorectal cancer; CT: computed 
tomography; CTLs: cytotoxic T lymphocytes; DAMPs: 
damage-associated molecular patterns; DCs: dendritic 
cells; DDX41: aspartate-glutamate-alanine-aspartate- 
box helicase 41; DFS: disease-free survival; DNA: 
deoxyribonucleic acid; dNTPs: deoxynucleotides; 
dsRNA: double-stranded ribonucleic acid; EDTA: 
ethylenediaminetetraacetic acid; p-eIF2α: phosphory-
lated-eukaryotic translation initiation factor 2 alpha; 
ER: endoplasmic reticulum; FDR: false discovery rate; 
FFPE: formalin-fixed paraffin-embedded; FOLFIRI: 
folinic acid, fluorouracil, irinotecan; FOLFOX: folinic 
acid, fluorouracil, oxaliplatin; FPR: false positive rate; 
GBP1: guanylate binding protein 1; H&E: 
hematoxylin and eosin; HIER: heat-induced epitope 
retrieval; HR: hazard ratio; ICD: immunogenic cell 
 Theranostics 2018, Vol. 8, Issue 12 
 
 
http://www.thno.org 
3212 
death; IFN: interferon; IHC: immunohistochemistry; 
ILN: infarct-like necrosis; IM: invasive margin; IQR: 
interquartile range; KRAS: kirsten rat sarcoma viral 
oncogene homolog; LASSO: least absolute shrinkage 
and selection operator; MLH1: MutL homolog 1; 
MMR: Mismatch repair; MRI: magnetic resonance 
imaging; MSH2: MutS protein homolog 2; mTRG: 
modified tumor regression grading; mut: mutant; 
Mx1: interferon-induced guanosine triphosphate- 
binding protein Mx1; OR: optimal response; OS: 
overall survival; PBS: phosphate-buffered saline; 
PCA: principal component analysis; PCR: polymerase 
chain reaction; PD: progressive disease; PET: 
positron-emission tomography; p-PKR: phosphory-
lated-protein kinase R; PR: partial response; RECIST: 
response evaluation criteria in solid tumors; 
REMARK: reporting recommendations for tumor 
marker prognostic studies; RFS: recurrence-free 
survival; RIG-I: retinoic acid inducible gene I; RT: 
room temperature; SAP: shrimp alkaline phosphatase; 
SD: stable disease; STING: stimulator of interferon 
genes; TAAs: tumor-associated antigens; Th1: T 
helper type 1; TME: tumor microenvironment; 
TOMOX: raltitrexed, oxaliplatin; TPR: true positive 
rate; TRG: tumor regression grading; TU: tumor; UN: 
usual necrosis; VEGF-A: vascular endothelial growth 
factor-A; wt: wild-type; XELIRI: capecitabine, 
irinotecan; XELOX: capecitabine, oxaliplatin; γH2AX: 
phosphorylated-histone H2AX. 
Supplementary Material  
Supplementary figures and tables. 
http://www.thno.org/v08p3198s1.pdf  
Acknowledgements 
Our special thanks go to Anna Obenauf 
(Research Institute of Molecular Pathology, Vienna, 
Austria) for her critical review and proofreading of 
the manuscript, as well as to Benjamin Loinger for 
drawing the graphical abstract. Furthermore, we 
would like to thank Lea Hunter for drawing the 
vector graphics, Marion Groeger (Core Facility 
Imaging, Medical University of Vienna, Vienna, 
Austria) for her expert help with the TissueFAXS 
scans and Margit Schmeidl (Department of Pathology, 
Medical University of Vienna, Vienna, Austria) for her 
excellent help with the tissue cutting. StrataQuest 
analysis was kindly supported by Robert Nica 
(TissueGnostics, Vienna, Austria).  
This study was in part supported by the Ludwig 
Boltzmann Institute Applied Diagnostics (lbi:ad), the 
Medical-Scientific Fund of the Mayor of Vienna (no. 
15071), as well as funds of the Medical University of 
Vienna. In addition, a personal research funding of 
the Fellinger Cancer Research and a personal research 
scholarship of the Medical University of Vienna was 
granted to J.L. to support this study. 
Author contributions 
J.L. and M.B. designed the study. J.S. provided 
histological samples. J.L., A.B. and B.H. performed 
immunohistochemistry. J.L. scanned and analyzed 
whole-slide tumor tissue. J.L., M.B., P.S. and S.S. 
provided clinical data and patient characteristics. D.T. 
and J.L. evaluated radiographic therapy response. J.S., 
J.L. and A.B. assessed pathologic therapy response. 
B.W. performed the mutation analysis. J.S. 
investigated the microsatellite status. D.P. and J.L. did 
the bioinformatics and performed the statistics. J.L., 
M.B, and D.P. analyzed and interpreted the results. 
J.L. wrote the manuscript. J.L., M.B. and D.P. edited 
the manuscript. M.B. supervised the study. All 
authors read and approved the final version of the 
manuscript. 
Ethics statement 
This study was conducted in accordance with 
the latest “Declaration of Helsinki” and “Good 
Scientific Practice Guidelines of the Medical 
University of Vienna”. Furthermore, the study 
protocol was verified by the “Ethics Committee of the 
Medical University of Vienna” (#1374/2014). Due to 
the retrospective nature of this study no informed 
consent was made. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Desch CE, Benson AB, 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et 
al. Colorectal cancer surveillance: 2005 update of an american society of 
clinical oncology practice guideline. J Clin Oncol. 2005; 23: 8512-9. 
2. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in 
metastatic colorectal cancer: A population-based study. Cancer. 2007; 109: 
718-26. 
3. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for 
predicting recurrence after hepatic resection for metastatic colorectal cancer: 
Analysis of 1001 consecutive cases. Ann Surg. 1999; 230:309-18; discussion 
18-21. 
4. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based 
study of the incidence, management and prognosis of hepatic metastases from 
colorectal cancer. Br J Surg. 2006; 93: 465-74. 
5. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in 
human tumours: Impact on clinical outcome. Nat Rev Cancer. 2012; 12: 
298-306. 
6. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. 
Prognostic and predictive values of the immunoscore in patients with rectal 
cancer. Clin Cancer Res. 2014; 20: 1891-9. 
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, 
et al. Type, density, and location of immune cells within human colorectal 
tumors predict clinical outcome. Science. 2006; 313: 1960-4. 
8. Koelzer VH, Lugli A, Dawson H, Hadrich M, Berger MD, Borner M, et al. 
Cd8/cd45ro t-cell infiltration in endoscopic biopsies of colorectal cancer 
predicts nodal metastasis and survival. J Transl Med. 2014; 12: 81. 
9. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. 
Histopathologic-based prognostic factors of colorectal cancers are associated 
with the state of the local immune reaction. J Clin Oncol. 2011; 29: 610-8. 
10. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. 
Effector memory t cells, early metastasis, and survival in colorectal cancer. N 
Engl J Med. 2005; 353: 2654-66. 
 Theranostics 2018, Vol. 8, Issue 12 
 
 
http://www.thno.org 
3213 
11. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman 
WH. Immune infiltration in human tumors: A prognostic factor that should 
not be ignored. Oncogene. 2010; 29: 1093-102. 
12. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In 
situ cytotoxic and memory t cells predict outcome in patients with early-stage 
colorectal cancer. J Clin Oncol. 2009; 27: 5944-51. 
13. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type i interferon 
response and innate immune sensing of cancer. Trends Immunol. 2013; 34: 
67-73. 
14. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, 
Melero I. Direct effects of type i interferons on cells of the immune system. 
Clin Cancer Res. 2011; 17: 2619-27. 
15. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type i interferons in 
anticancer immunity. Nat Rev Immunol. 2015; 15: 405-14. 
16. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. 
Dissecting the tumor myeloid compartment reveals rare activating 
antigen-presenting cells critical for t cell immunity. Cancer Cell. 2014; 26: 
638-52. 
17. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, 
Archambault JM, et al. Type i interferon is selectively required by dendritic 
cells for immune rejection of tumors. J Exp Med. 2011; 208: 1989-2003. 
18. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host 
type i ifn signals are required for antitumor cd8+ t cell responses through 
cd8{alpha}+ dendritic cells. J Exp Med. 2011; 208: 2005-16. 
19. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, et al. Type i ifns 
control antigen retention and survival of cd8alpha(+) dendritic cells after 
uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011; 186: 
5142-50. 
20. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. 
Macrophage il-10 blocks cd8+ t cell-dependent responses to chemotherapy by 
suppressing il-12 expression in intratumoral dendritic cells. Cancer Cell. 2014; 
26: 623-37. 
21. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer 
cell-autonomous contribution of type i interferon signaling to the efficacy of 
chemotherapy. Nat Med. 2014; 20: 1301-9. 
22. Klarquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM. 
Sting-mediated DNA sensing promotes antitumor and autoimmune responses 
to dying cells. J Immunol. 2014; 193: 6124-34. 
23. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. 
Sting-dependent cytosolic DNA sensing mediates innate immune recognition 
of immunogenic tumors. Immunity. 2014; 41: 830-42. 
24. Barber GN. Sting-dependent cytosolic DNA sensing pathways. Trends 
Immunol. 2014; 35: 88-93. 
25. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. 
Sting is a direct innate immune sensor of cyclic di-gmp. Nature. 2011; 478: 
515-8. 
26. Cai X, Chiu YH, Chen ZJ. The cgas-cgamp-sting pathway of cytosolic DNA 
sensing and signaling. Mol Cell. 2014; 54: 289-96. 
27. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. Sting-dependent 
cytosolic DNA sensing promotes radiation-induced type i 
interferon-dependent antitumor immunity in immunogenic tumors. 
Immunity. 2014; 41: 843-52. 
28. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. 
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat 
Med. 2007; 13: 54-61. 
29. Grenz S, Naschberger E, Merkel S, Britzen-Laurent N, Schaal U, Konrad A, et 
al. Ifn-gamma-driven intratumoral microenvironment exhibits superior 
prognostic effect compared with an ifn-alpha-driven microenvironment in 
patients with colon carcinoma. Am J Pathol. 2013; 183: 1897-909. 
30. Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T, et al. 
Oncogenic ki-ras inhibits the expression of interferon-responsive genes 
through inhibition of stat1 and stat2 expression. J Biol Chem. 2003; 278: 
46278-87. 
31. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure 
time. Control Clin Trials. 1996; 17: 343-6. 
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. 
Reporting recommendations for tumor marker prognostic studies (remark). 
Breast Cancer Res Treat. 2006; 100: 229-35. 
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. 
New response evaluation criteria in solid tumours: Revised recist guideline 
(version 1.1). Eur J Cancer. 2009; 45: 228-47. 
34. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz S, et al. 
Ct findings of response and recurrence, independent of change in tumor size, 
in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 
2011; 197: W1060-6. 
35. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, 
et al. Association of computed tomography morphologic criteria with 
pathologic response and survival in patients treated with bevacizumab for 
colorectal liver metastases. JAMA. 2009; 302: 2338-44. 
36. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, et al. 
Optimal morphologic response to preoperative chemotherapy: An alternate 
outcome end point before resection of hepatic colorectal metastases. J Clin 
Oncol. 2012; 30: 4566-72. 
37. Chang HH, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like necrosis: A 
distinct form of necrosis seen in colorectal carcinoma liver metastases treated 
with perioperative chemotherapy. Am J Surg Pathol. 2012; 36: 570-6. 
38. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. 
Importance of histological tumor response assessment in predicting the 
outcome in patients with colorectal liver metastases treated with neo-adjuvant 
chemotherapy followed by liver surgery. Ann Oncol. 2007; 18: 299-304. 
39. Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, et al. 
Histopathologic evaluation of liver metastases from colorectal cancer in 
patients treated with folfoxiri plus bevacizumab. Br J Cancer. 2013; 108: 
2549-56. 
40. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, et al. 
Kras status and outcome of liver resection after neoadjuvant chemotherapy 
including bevacizumab. Br J Surg. 2012; 99: 1575-82. 
41. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. 
Immunohistochemical pattern of mlh1/msh2 expression is related to clinical 
and pathological features in colorectal adenocarcinomas with microsatellite 
instability. Mod Pathol. 2002; 15: 741-9. 
42. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. 
Immunohistochemical test for mlh1 and msh2 expression predicts clinical 
outcome in stage ii and iii colorectal cancer patients. J Clin Oncol. 2006; 24: 
2359-67. 
43. Team RC. R: A language and environment for statistical computing. Vienna, 
Austria: R Foundation for Statistical Computing; 2017. 
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and 
powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 
1995; 57: 289-300. 
45. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death 
in cancer and infectious disease. Nat Rev Immunol. 2017; 17: 97-111. 
46. Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA 
damage and repair biomarkers of immunotherapy response. Cancer Discov. 
2017; 7: 675-93. 
47. Rufo N, Garg AD, Agostinis P. The unfolded protein response in 
immunogenic cell death and cancer immunotherapy. Trends Cancer. 2017; 3: 
643-58. 
48. Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune 
responses. Nat Rev Immunol. 2017; 17: 262-75. 
49. Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate 
immunity: Links and trade-offs. Trends Immunol. 2014; 35: 429-35. 
50. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity. 2013; 38: 870-80. 
51. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et 
al. Γh2ax and cancer. Nat Rev Cancer. 2008; 8: 957-67. 
52. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between 
survival and death in cancer biology. Nat Rev Cancer. 2016; 16: 20-33. 
53. Yang SX, Polley EC, Nguyen D. Association of γh2ax at diagnosis with 
chemotherapy outcome in patients with breast cancer. Theranostics. 2017; 7: 
945-51. 
54. Liu X, Li F, Huang Q, Zhang Z, Zhou L, Deng Y, et al. Self-inflicted DNA 
double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell 
Res. 2017; 27: 764-83. 
55. He L, Xiao X, Yang X, Zhang Z, Wu L, Liu Z. Sting signaling in tumorigenesis 
and cancer therapy: A friend or foe? Cancer Lett. 2017; 402: 203-12. 
56. Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, 
et al. Comprehensive intrametastatic immune quantification and major impact 
of immunoscore on survival. J Natl Cancer Inst. 2018; 110: 1-12. 
57. Peng R-Q. Expression of calreticulin is associated with infiltration of t-cells in 
stage iiib colon cancer. World J Gastroenterol. 2010; 16: 2428-34. 
58. Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, et al. Calreticulin 
expression: Interaction with the immune infiltrate and impact on survival in 
patients with ovarian and non-small cell lung cancer. Oncoimmunology. 2016; 
5: e1177692. 
59. Knight JC, Mosley MJ, Bravo LC, Kersemans V, Allen PD, Mukherjee S, et al. 
(89)zr-anti-γh2ax-tat but not (18)f-fdg allows early monitoring of response to 
chemotherapy in a mouse model of pancreatic ductal adenocarcinoma. Clin 
Cancer Res. 2017; 23: 6498-504. 
 
